MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 916 productos para "MAPK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Antimicrobial agent-21
CAS:Antimicrobial agent-21 is a potent mitogen activated protein kinase inhibitor with antibacterial, anti-inflammatory and antitumor activity for the treatment ofFórmula:C18H13N3OSPureza:99.82%Forma y color:SolidPeso molecular:319.38Mitogen-activated protein kinase 1
CAS:Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.Pureza:98%Forma y color:SolidADT-007
CAS:ADT-007 is a pan-RAS inhibitor with potent anticancer activity.Fórmula:C26H24FNO5Pureza:98.82%Forma y color:Yellow SolidPeso molecular:449.47Ref: TM-T85316
1mg47,00€5mg96,00€1mL*10mM (DMSO)104,00€10mg124,00€25mg200,00€50mg353,00€100mg602,00€200mg982,00€RTIL 13
CAS:RTIL 13 inhibits dynamin GTPase (IC50: 2.3 μM), targets its lipid binding domain, and suppresses endocytosis (IC50: 9.3 & 7.1 μM).Fórmula:C30H55BrN2O3Forma y color:SolidPeso molecular:571.685GNE-9815
CAS:GNE-9815 (3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide) is a high kinase-selectiveFórmula:C26H22FN5O2Pureza:99.08% - 99.1%Forma y color:SolidPeso molecular:455.48Ref: TM-T9585
1mg60,00€5mg138,00€1mL*10mM (DMSO)138,00€10mg215,00€25mg358,00€50mg510,00€100mg692,00€500mg1.386,00€NecroX-2
CAS:NecroX-2 is a cell-permeable necrosis inhibitor with antioxidant properties. NecroX-2 selectively suppresses necrotic cell death triggered by oxidative stress. NecroX-2 does not confer protection against apoptosis induced by staurosporine or etoposide but shows protective effects under conditions such as cold shock, hypoxia, and oxidative stress in vitro.Fórmula:C25H32N4O4S2Pureza:97.12%Forma y color:SolidPeso molecular:516.68KRAS inhibitor-38
CAS:KRAS Inhibitor-38 (Example 18) is a potent inhibitor capable of effectively suppressing the activity of KRAS G12C, KRAS G12D, and KRAS G12V in vivo.Fórmula:C53H68ClF2N9O8SForma y color:SolidPeso molecular:1064.68JTP10-△-TATi TFA
JTP10-△-TATi TFA is a selective inhibitor of JNK2 peptide (IC50: 92 nM), exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.Fórmula:C120H213F3N48O28Pureza:98%Forma y color:SolidPeso molecular:2833.28Cobimetinib (R-enantiomer)
CAS:Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib which is a selective MEK inhibitor.Fórmula:C21H21F3IN3O2Pureza:98%Forma y color:SolidPeso molecular:531.318KRAS G12C inhibitor 20
CAS:KRAS G12C inhibitor 20 is a KRAS G12C inhibitor.Fórmula:C33H37ClFN7O3Forma y color:SolidPeso molecular:634.14(RS)-G12Di-1
(RS)-G12Di-1 is a selective covalent inhibitor of K-Ras-G12D.Fórmula:C37H35FN6O4Forma y color:SolidPeso molecular:646.27038MS432
MS432 is a highly selective PD0325901-based VHL-recruiting PROTAC degrader for MEK1 and MEK2.Fórmula:C50H65F3IN7O6SPureza:98%Forma y color:SolidPeso molecular:1076.06FAM49B (190-198) mouse
CAS:FAM49B (190-198) mouse represents a peptide fragment of the mitochondria-localized protein FAM49B, which is instrumental in regulating mitochondrial fission, function, and integrity, in addition to influencing tumor progression. Beyond its role in mitochondrial dynamics, FAM49B serves as a negative regulator of T cell activation by inhibiting GTPase Rac activity and affecting cytoskeleton reorganization.Fórmula:C49H71N9O14SForma y color:SolidPeso molecular:1042.2HPK1-IN-4
CAS:HPK1-IN-4 is an HPK1 (MAPK41) inhibitor with an IC 50 of 0.061 nM. HPK1-IN-4 is often used as a preclinical immunotherapy tool compound.Fórmula:C23H26N6O3Pureza:97.06%Forma y color:Yellow SolidPeso molecular:434.49Ref: TM-T40350
1mg123,00€5mg295,00€1mL*10mM (DMSO)326,00€10mg447,00€25mg782,00€50mg1.071,00€100mg1.468,00€PROTAC ERK5 degrader-1
CAS:PROTACERK5 degrader-1 (compound 2) is a bifunctional ERK5 PROTAC degrader. It induces the degradation of ERK5 in MOLT-4 cells via a VHL-mediated proteasome pathway. PROTACERK5 degrader-1 is useful for studying diseases or disorders characterized by abnormal ERK5 activity.Fórmula:C54H67F3N10O6SForma y color:SolidPeso molecular:1041.23(S,R,S)-AHPC-Me-C10-Br
CAS:(S,R,S)-AHPC-Me-C10-Br is a chemically synthesized conjugate and ligand-linker for E3 ligase, MS432 for MEK1/2 inhibitors and a VHL E3 ligase linker.Fórmula:C34H51BrN4O4SPureza:98.89%Forma y color:SolidPeso molecular:691.76ASP6918
ASP6918 is a potent, orally active KRAS G12C inhibitor with an IC50 of 0.028 µM. It inhibits cell growth and demonstrates antitumor activity.Fórmula:C36H43N7O3Forma y color:SolidPeso molecular:621.34274Fluconazole-PEG6-XMU-MP-9
Fluconazole-PEG6-XMU-MP-9, PEG-linked conjugate, fluconazole antifungal plus XMU-MP-9, promotes Nedd4-1 mediated K-Ras mutant degradation.Fórmula:C48H53F3N10O10SPureza:98.73%Forma y color:Yellow SolidPeso molecular:1019.06ERK1/2 inhibitor 10
ERK1/2 inhibitor 10 (Compound 36c) is a potent inhibitor of ERK1 and ERK2, with IC50 values of 0.11 nM and 0.08 nM, respectively. It effectively hinders the phosphorylation of downstream substrates p90RSK and c-Myc. Additionally, ERK1/2 inhibitor 10 induces apoptosis and incomplete autophagy-related cell death. This compound demonstrates significant antitumor efficacy in models of triple-negative breast cancer and colorectal cancer harboring BRAF and RAS mutations.Fórmula:C23H20ClN5O2SPeso molecular:465.10262KRAS-IN-43
KRAS-IN-43 (Compound 9) is a broad-spectrum KRAS inhibitor with IC50 values of 0.15 μM for KRASG12V, 0.14 μM for KRASG12C, and 0.47 μM for wild-type KRAS. It disrupts the interaction between KRAS and cRAF and suppresses ERK phosphorylation. KRAS-IN-43 shows potential for research in KRAS mutation-associated cancers, including pancreatic, colorectal, and lung cancers.Forma y color:Odour Solid
